- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. To schedule a demo, contact us at sales@docketalarm.com or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 39-53 of
155 results
2019 Exhibit: Jacobs, M, Mechanism of Action of Hydralzaine on Vascular Smooth ...
Document
IPR2025-01139, No. 2019 Exhibit - Jacobs, M, Mechanism of Action of Hydralzaine on Vascular Smooth Muscle, BIOCHEM PHARMACOL (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1050 Exhibit: EX 1050 Actelion Pending Litigation
Document
IPR2025-01139, No. 1050 Exhibit - EX 1050 Actelion Pending Litigation (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2012 Exhibit: Claim 1 of the ’847 patent compared to CA ’770 patent
Document
IPR2025-01139, No. 2012 Exhibit - Claim 1 of the ’847 patent compared to CA ’770 patent (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2006 Exhibit: Orange Book Entry for OPSUMIT®
Document
IPR2025-01139, No. 2006 Exhibit - Orange Book Entry for OPSUMIT® (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2004 Exhibit: US FDA Approves OPSYNVI® macitentan and tadalafil as the First and...
Document
IPR2025-01139, No. 2004 Exhibit - US FDA Approves OPSYNVI® macitentan and tadalafil as the First and Only Once Daily Single Tablet Combination Therapy for Patients with Pulmonary Arteria...
|
|
Cite Document
2011 Exhibit: Decision of Canadian Court in Janssen, Inc et al v Sandoz Canada Inc...
Document
IPR2025-01139, No. 2011 Exhibit - Decision of Canadian Court in Janssen, Inc et al v Sandoz Canada Inc Court File No T 549 20, 2022 FC 715 Fed Ct May 31, 2022, appeal dismissed, Sandoz Ca...
|
|
Cite Document
2008 Exhibit: Clinicaltrialsgov entry for the SERAPHIN study re OPSUMIT® maciten...
Document
IPR2025-01139, No. 2008 Exhibit - Clinicaltrialsgov entry for the SERAPHIN study re OPSUMIT® macitentan (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2005 Exhibit: FDA approves Opsumit to treat pulmonary arterial hypertension Oct 1...
Document
IPR2025-01139, No. 2005 Exhibit - FDA approves Opsumit to treat pulmonary arterial hypertension Oct 18, 2013 (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2014 Exhibit: Research and Development in the Pharmaceutical Industry, Congres...
Document
IPR2025-01139, No. 2014 Exhibit - Research and Development in the Pharmaceutical Industry, Congressional Budget Office April 2021 (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2003 Exhibit: United Therapeutics, Our History Timeline
Document
IPR2025-01139, No. 2003 Exhibit - United Therapeutics, Our History Timeline (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2001 Exhibit: United Therapeutics Form 10K Annual Report for 2013
Document
IPR2025-01139, No. 2001 Exhibit - United Therapeutics Form 10K Annual Report for 2013 (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2009 Exhibit: Clinicaltrialsgov entry to the A DUE study re OPSYNVI® macitentantad...
Document
IPR2025-01139, No. 2009 Exhibit - Clinicaltrialsgov entry to the A DUE study re OPSYNVI® macitentantadalafil in one dose (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2013 Exhibit: A Sertkaya et al, Costs of Drug Development and Research and Deve...
Document
IPR2025-01139, No. 2013 Exhibit - A Sertkaya et al, Costs of Drug Development and Research and Development Intensity in the US, 2000 2018, JAMA Network Open 202476e2415445 June 8, 2...
|
|
Cite Document
2007 Exhibit: Orange Book Entry for OPSYNVI®
Document
IPR2025-01139, No. 2007 Exhibit - Orange Book Entry for OPSYNVI® (P.T.A.B. Sep. 2, 2025)
|
|
Cite Document
2015 Exhibit: OPSYNVI® macitentan and tadalafil Becomes the First and Only Heal...
Document
IPR2025-01139, No. 2015 Exhibit - OPSYNVI® macitentan and tadalafil Becomes the First and Only Health Canada Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulm...
|
|
Cite Document
